Orexin-A inhibits cerebral ischaemic inflammatory injury mediated by the nuclear factor-κB signalling pathway and alleviates stroke-induced immunodepression in mice

Brain Res Bull. 2021 Sep:174:296-304. doi: 10.1016/j.brainresbull.2021.06.021. Epub 2021 Jun 30.

Abstract

Cerebral ischaemia is accompanied by infectious complications due to immunosuppression, known as stroke-induced immunodepression (SIID). Orexin-A (OXA), a neuropeptide produced in the hypothalamus, has been reported to have neuroprotective properties after stroke and is known to modulate inflammatory processes in peripheral tissues. The aim of this study was to determine the effects of orexin-A (OXA) on cerebral ischaemic inflammatory injury and SIID following experimental stroke. Cerebral ischaemia was induced in C57/BL6 mice by middle cerebral artery occlusion (MCAO). A mouse model of pneumonia and poststroke pneumococcal pneumonia was established by intratracheal inoculation with S. pneumoniae in a normal mouse or MCAO mouse model on the third day. We found that OXA postconditioning inhibited cerebral ischaemic inflammatory injury. The mechanism involved downregulation of the NF-κB signalling pathway. In addition, OXA may serve as a potential treatment target for attenuating stroke-induced immunodepression in mice.

Keywords: Cerebral ischaemic inflammatory injury; Nuclear factor-κB signalling pathway; Orexin-A; Stroke-induced immunodepression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy*
  • Encephalitis / drug therapy*
  • Immune Tolerance / drug effects
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NF-kappa B / drug effects*
  • Neuroprotective Agents / therapeutic use*
  • Pneumococcal Infections / complications
  • Pneumococcal Infections / drug therapy
  • Pneumococcal Infections / pathology
  • Signal Transduction / drug effects*
  • Stroke / drug therapy
  • Stroke / immunology*
  • Transcription Factor RelA / therapeutic use*

Substances

  • NF-kappa B
  • Neuroprotective Agents
  • Rela protein, mouse
  • Transcription Factor RelA